London: A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history, with potential sales of $35 billion a year.
The sales forecast by analysts at US bank Citigroup highlights the growing excitement surrounding so-called immunotherapy after positive results from clinical trials conducted by companies such as Bristol-Myers Squibb and Roche Holding.
"We believe this market will generate sales of up to $35 billion (a year) over the next 10 years and be used in some way in the management of up to 60 per cent of all cancers," Citi analyst Andrew Baum said on Wednesday.
Citi's forecast is considerably higher than current market consensus, but if it proves correct, then cancer immunotherapy would exceed the peak market value of top blockbuster drug classes such as statins for high cholesterol....
more
09:59 AM, May 23, 2013
Prathiba M Singh, advocate for Ranbaxy and Cipla, fought the Glivec patent case against Novartis. She joined IBNLive readers for an interaction on the legal and moral compulsions behind this courtroom battle and the significance of the Supreme Court's decision for Indian pharma firms and the people of the country. ...
06:33 PM, Apr 03, 2013
The US industry on Wednesday said it is reviewing the order of the Supreme Court early this week that denied patent on Glivec, a cancer medication produced by Swiss drug maker Novartis, as Corporate America expressed dismay at the court verdict. ...
01:00 PM, Apr 03, 2013
Expressing unease over the Supreme Court ruling against pharmaceutical giant Novartis denying the company a patent on its cancer drug, a major business advocacy group on Tuesday said that this would impact innovation and investment climate in India at a time when the country needs foreign direct investment the most. ...
10:43 AM, Apr 03, 2013
In a landmark verdict, the Supreme Court of India dismissed a plea by the Swiss pharmaceutical giant Novartis on Monday for a patent on its cancer drug Glivec, paving way for more affordable life saving drug. ...
11:31 PM, Apr 02, 2013
New Delhi: In a landmark verdict, the Supreme Court of India dismissed a plea by the Swiss pharmaceutical giant Novartis on Monday for a patent on its cancer drug Glivec, paving way for more affordable life saving cancer drugs. Novartis had sought to overturn a clause in Indian Patents Law that restricts patent protection for newer forms of existing molecules, and the ruling could set a precedent for how other...
11:05 AM, Apr 01, 2013
Mumbai: After the Indian government recently lifted a patent license, Indian pharma major, Cipla, has announced a massive reduction of up to 76 per cent in its cancer drug prices. Following the move, the price of Cipla's generic kidney cancer drug, Sorafenib, will be available at Rs 6,840 a month from the earlier Rs 27,950. The lung cancer drug Gestinib price has been cut down by 60 per cent to...
07:51 AM, May 05, 2012
The court’s decision has come as a big relief to Indian companies. ...
04:26 PM, Aug 08, 2007
